Yong‐ju Liang

2.6k total citations
43 papers, 2.2k citations indexed

About

Yong‐ju Liang is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Yong‐ju Liang has authored 43 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 27 papers in Oncology and 10 papers in Organic Chemistry. Recurrent topics in Yong‐ju Liang's work include Drug Transport and Resistance Mechanisms (23 papers), Cancer therapeutics and mechanisms (16 papers) and Synthesis and biological activity (9 papers). Yong‐ju Liang is often cited by papers focused on Drug Transport and Resistance Mechanisms (23 papers), Cancer therapeutics and mechanisms (16 papers) and Synthesis and biological activity (9 papers). Yong‐ju Liang collaborates with scholars based in China, United States and Hong Kong. Yong‐ju Liang's co-authors include Liwu Fu, Zhe‐Sheng Chen, Chun-ling Dai, Liming Chen, Suresh V. Ambudkar, Amit K. Tiwari, Kenneth K.W. To, Fang Wang, Yan‐jun Mi and Yan‐yan Yan and has published in prestigious journals such as PLoS ONE, Cancer Research and International Journal of Cancer.

In The Last Decade

Yong‐ju Liang

42 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yong‐ju Liang China 27 1.4k 1.1k 306 284 220 43 2.2k
Kristen M. Pluchino United States 10 1.1k 0.8× 1.0k 0.9× 168 0.5× 160 0.6× 207 0.9× 14 2.0k
Yi‐Jun Wang United States 29 1.6k 1.2× 982 0.9× 161 0.5× 203 0.7× 209 0.9× 75 2.5k
Tomoko Oh‐hara Japan 31 1.7k 1.3× 2.0k 1.8× 237 0.8× 400 1.4× 123 0.6× 65 3.4k
Zi‐Ning Lei United States 29 1.2k 0.9× 1.2k 1.1× 174 0.6× 192 0.7× 322 1.5× 72 2.2k
Lakshmi Pendyala United States 27 1.1k 0.8× 1.1k 1.0× 207 0.7× 337 1.2× 69 0.3× 96 2.3k
Chao‐Yun Cai China 24 849 0.6× 862 0.8× 216 0.7× 106 0.4× 210 1.0× 40 1.6k
William R. Waud United States 30 606 0.4× 1.6k 1.4× 418 1.4× 233 0.8× 166 0.8× 81 2.8k
Shin‐ichi Akiyama Japan 26 1.5k 1.1× 1.3k 1.2× 132 0.4× 83 0.3× 251 1.1× 40 2.4k
Yoji Ikegami Japan 19 1.2k 0.9× 1.2k 1.0× 146 0.5× 155 0.5× 206 0.9× 43 1.9k
Chun-ling Dai China 16 992 0.7× 695 0.6× 67 0.2× 188 0.7× 184 0.8× 19 1.4k

Countries citing papers authored by Yong‐ju Liang

Since Specialization
Citations

This map shows the geographic impact of Yong‐ju Liang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yong‐ju Liang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yong‐ju Liang more than expected).

Fields of papers citing papers by Yong‐ju Liang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yong‐ju Liang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yong‐ju Liang. The network helps show where Yong‐ju Liang may publish in the future.

Co-authorship network of co-authors of Yong‐ju Liang

This figure shows the co-authorship network connecting the top 25 collaborators of Yong‐ju Liang. A scholar is included among the top collaborators of Yong‐ju Liang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yong‐ju Liang. Yong‐ju Liang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xie, Jing‐Dun, Xu Zhang, Yong‐ju Liang, et al.. (2012). Neratinib Reverses ATP-Binding Cassette B1-Mediated Chemotherapeutic Drug Resistance In Vitro, In Vivo, and Ex Vivo. Molecular Pharmacology. 82(1). 47–58. 82 indexed citations
2.
Wang, Fang, et al.. (2012). ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties. Chinese Journal of Cancer. 31(3). 150–158. 2 indexed citations
3.
Yan, Yan‐yan, Li-Sheng Zheng, Xu Zhang, et al.. (2011). Blockade of Her2/neu Binding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/neu. Molecular Pharmaceutics. 8(5). 1687–1697. 45 indexed citations
4.
Zhang, Jianye, Yan‐jun Mi, Fang Wang, et al.. (2011). Euphorbia factor L1 reverses ABCB1‐mediated multidrug resistance involving interaction with ABCB1 independent of ABCB1 downregualtion. Journal of Cellular Biochemistry. 112(4). 1076–1083. 22 indexed citations
5.
Liang, Yong‐ju, et al.. (2011). Synthesis and Biological Evaluation of Novel (Thio)Urea Derivatives as Potential Antitumor Agents. Archiv der Pharmazie. 344(11). 741–744.
6.
Wang, Fang, Yong‐ju Liang, Liming Chen, et al.. (2011). Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. European Journal of Cancer. 47(13). 1990–1999. 18 indexed citations
7.
Mi, Yan‐jun, Yong‐ju Liang, Hong-Yun Zhao, et al.. (2010). Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Research. 70(20). 7981–7991. 288 indexed citations
8.
9.
Wang, Xiaohong, Yong‐ju Liang, Zhi Shi, et al.. (2010). A cell-based screen for anticancer activity of 13 pyrazolone derivatives. Chinese Journal of Cancer. 29(12). 980–987. 36 indexed citations
10.
Liang, Yong‐ju, et al.. (2010). Synthesis and antitumor activity of ureas containing pyrimidinyl group. European Journal of Medicinal Chemistry. 46(1). 429–432. 34 indexed citations
11.
Yuan, Shuqiang, Zhi-Wei Zhou, Yong‐ju Liang, et al.. (2009). Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues. Chinese Journal of Cancer. 28(9). 932–938. 4 indexed citations
12.
Dai, Chun-ling, Yong‐ju Liang, Xu Zhang, et al.. (2009). Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochemical Pharmacology. 78(4). 355–364. 25 indexed citations
13.
Dai, Chun-ling, Yong‐ju Liang, Amit K. Tiwari, et al.. (2009). Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Letters. 279(1). 74–83. 101 indexed citations
14.
Zheng, Li-Sheng, Fang Wang, Yuhong Li, et al.. (2009). Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function. PLoS ONE. 4(4). e5172–e5172. 75 indexed citations
15.
Huang, Xinan, et al.. (2009). Four new cytotoxic oligosaccharidic derivatives of 12-oleanene from Lysimachia heterogenea Klatt. Bioorganic & Medicinal Chemistry Letters. 19(23). 6515–6518. 8 indexed citations
16.
Zhang, Jianye, Yong‐ju Liang, Yan‐yan Yan, et al.. (2009). Secalonic Acid D induced leukemia cell apoptosis and cell cycle arrest of G1 with involvement of GSK-3β/β-catenin/c-Myc pathway. Cell Cycle. 8(15). 2444–2450. 85 indexed citations
17.
Dai, Chun-ling, Amit K. Tiwari, Chung‐Pu Wu, et al.. (2008). Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research. 68(19). 7905–7914. 333 indexed citations
18.
Liang, Yong‐ju, et al.. (2007). FG020326-loaded nanoparticle with PEG and PDLLA improved pharmacodynamics of reversing multidrug resistance in vitro and in vivo. Acta Pharmacologica Sinica. 28(6). 913–920. 13 indexed citations
19.
20.
Chen, Liming, Yong‐ju Liang, Yan Ding, et al.. (2004). Screening Novel, Potent Multidrug-Resistant Modulators From Imidazole Derivatives. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 14(7). 355–362. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kristen M. Pluchino Breakdown of academic impact, for papers by Yi‐Jun Wang Breakdown of academic impact, for papers by Tomoko Oh‐hara Breakdown of academic impact, for papers by Zi‐Ning Lei Breakdown of academic impact, for papers by Lakshmi Pendyala Breakdown of academic impact, for papers by Chao‐Yun Cai Breakdown of academic impact, for papers by William R. Waud Breakdown of academic impact, for papers by Shin‐ichi Akiyama Breakdown of academic impact, for papers by Yoji Ikegami Breakdown of academic impact, for papers by Chun-ling Dai
Rankless by CCL
2026